This is a preview of subscription content, log in via an institution to check access.
References
Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 2002; 62(4): 705–22
Cardoso F, Jankovic J. Dystonia and dyskinesia. Psychiatr Clin North Am 1997 Dec; 20: 821–38
Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53: 1439–46
Brin MF, Lew MF, Alder CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type-A resistant cervical dystonia. Neurology 1999; 53: 1431–8
Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997 Sep; 49: 701–7
Elan Pharmaceuticals Inc. Myobloc, botulinum toxin type B injectable solution. Prescribing information. Elan Pharmaceuticals, Inc., South San Francisco, USA. 2000 Dec
Elan Pharmaceuticals Europe. NeuroBloc prescribing information. Elan Pharmaceuticals Europe, Stevenage, Herts., UK; 2001 Apr
Rights and permissions
About this article
Cite this article
Botulinum toxin B reduces the severity, pain and disability of cervical dystonia. Drugs Ther. Perspect 18, 1–3 (2002). https://doi.org/10.2165/00042310-200218110-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200218110-00001